22 results about "Brains tissue" patented technology

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.

The present application belongs to the field of functional substance research, and particularly relates to a nutritional composition for promoting brain development and use thereof. The nutritional composition provided by the present application comprises essential active ingredients shown in (i) and (ii) as follows: (i) lysophosphatidylethanolamine; (ii) 3'-SL; wherein the essential active ingredient shown in (i) at least comprises lysophosphatidylethanolamine with a fatty acid chain with a length of 14-22 carbon atoms connected at the sn-1 position, and in the nutritional composition, the mass ratio of the essential active ingredient shown in (i) to the essential active ingredient shown in (ii) is 1:(1-450). The combination of lysophosphatidylethanolamine and breast milk oligosaccharide 3'-SL can effectively promote the overall development of the body, especially the brain development, and improve the relative gene expression amount of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, thereby effectively assisting the improvement of cognitive ability.

The application provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is composed of nacre, antelope horn powder, dragon's blood, Herba Schizonepetae, Prunella vulgaris, Stink-bug, Smilax riparia, bamboo juice, dried tangerine or orange peel, clubmoss, radix puerariae, Zizania aquatica and leaf of Chinese pear. The preparation has a significant therapeutic effect on cerebral hemorrhage, can obviously improve the neurological deficit of cerebral hemorrhage rats, reduce the water content of brain tissue to alleviate brain edema, simultaneously alleviate the inflammatory response in the body, thereby playing a neuroprotective effect on cerebral hemorrhage rats. In addition, the preparation can obviously improve the consciousness state of cerebral hemorrhage patients, alleviate the degree of neurological deficit, relieve the related TCM syndromes of the patients, simultaneously effectively improve the daily life ability of the patients, significantly improve the total effective rate of clinical treatment, and no obvious adverse reactions are observed in the treatment process, and the safety is good, thereby providing a safe and effective treatment scheme for the conservative treatment of cerebral hemorrhage.

The present application provides a kind of nutritional composition and its application in the preparation of protecting brain barrier health product.The nutritional composition provided by the present application includes animal bifidobacterium lactis subsp CP-9 and 3'-sialyllactose, the present application has been confirmed from histological level: the expression of occludin and claudin-5 in brain tissue can be improved after the nutritional composition of animal bifidobacterium lactis subsp CP-9 and 3'-sialyllactose is applied to organism, so as to strengthen the integrity and occlusion of brain barrier structure, promote the maturation and function perfection of blood-brain barrier, cerebrospinal fluid barrier and other brain barrier system, to realize the effect of enhancing brain barrier function, promoting brain barrier development and other maintenance brain barrier health.

The present application belongs to the technical field of nutrient research, and particularly relates to a nutrient composition for promoting brain development and use thereof. The nutrient composition provided by the present application comprises two necessary components: i) lysophosphatidyl ethanolamine; and ii) docosahexaenoic acid; and the mass ratio of the lysophosphatidyl ethanolamine to the docosahexaenoic acid in the nutrient composition is 1:(10-2100). The combination of lysophosphatidyl ethanolamine and docosahexaenoic acid can effectively promote the overall growth and development of the body, especially the brain development, increase the expression levels of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, and effectively assist the improvement of cognitive ability.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

The application discloses discovery and application of desmin autoantibody as a marker of nervous system diseases. The application finds that only the fluorescent signal existing in the nervous system disease patients but not in the healthy people, and the fluorescent mode of the IgG related autoimmune antibody in the mouse brain tissue section is different, which indicates that the patient may have autoimmune antibody. Through the immunoprecipitation technology, the IgG specific protein related to the nervous system disease is sought, the specific desmin autoantibody is found by adopting the CBA mode, and then the desmin autoantibody is verified in the cerebrospinal fluid, so that it is finally determined that the desmin autoantibody can be used as a specific marker for diagnosing the nervous system autoimmune diseases. The expression of the desmin autoantibody is detected by taking the desmin as a detection antigen, and the detection of the desmin autoantibody can be applied to a kit for detecting the desmin autoantibody, and can be applied to the detection of the nervous system diseases, so that the marker for identifying the nervous system diseases is enriched, and the accuracy of the detection of the nervous system related diseases is improved.

The application discloses application of ginsenoside F4 in preparation of PPAR gamma agonists and medicines for preventing and treating depression, and relates to the technical field of biological medicines.The application proves that the ginsenoside F4 is a new and efficient PPAR gamma agonist, can specifically combine with and significantly activate the transcription activity of PPAR gamma, and simultaneously up-regulate the protein expression of PPAR gamma in brain tissues.Through inhibiting the over-activation of microglial cells, the ginsenoside F4 significantly reduces the release of pro-inflammatory cytokines (such as IL-1beta, TNF-alpha, IL-6 and the like) in the brain, inhibits inflammation in the central nervous system, further prevents and treats depression, and the effect is more significant than that of a PPAR gamma complete agonist (such as rosiglitazone and the like).The ginsenoside F4 has target selectivity, can exert an anti-depression effect while not affecting the metabolic homeostasis of the body periphery, and avoids systemic toxic side effects such as abnormal weight increase caused by the existing PPAR gamma complete agonist (such as rosiglitazone and the like).

The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.

The present invention provides an application of α-asarone in the preparation of a medicine for preventing or treating hemorrhagic strokes. α-asarone has the structure shown in formula I, and may significantly improve short-term neurological deficits and long-term learning and memory functions of model rats, reduce cerebral edema, improve the permeability of the blood-brain barrier, and prevent or mitigate the atrophy of brain tissue during a recovery period. α-asarone has a precise therapeutic effect on animal models of hemorrhagic stroke without obvious toxic side effects, and is expected to have great application prospects as a medicine for preventing / treating hemorrhagic strokes.

Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased transduction enrichment in the brain and, in some cases, reduced transduction in the liver. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. Gene therapy using the rAAVs is described. Also described are methods of treating brain-related diseases and conditions.

The application belongs to the technical field of traditional Chinese medicine, and discloses application of uniform lily rehmannia polysaccharide in preparation of a medicine for treating cerebral ischemia, wherein the uniform lily rehmannia polysaccharide is composed of galactose, glucose and fructose in a molar ratio of 2.25:18.98:78.77. The uniform lily rehmannia polysaccharide obtained by the application has fixed components, and the uniform lily rehmannia polysaccharide protects brain tissues from damage caused by cerebral ischemia by regulating cGAS-STING signal transmission, which greatly promotes the industrialization process of lily rehmannia and the application range thereof.

This disclosure provides (i) a benzo[c][1,2,5]thiadiazolyl-based target ligand that can bind to toxic peptides and / or protein aggregates in brain tissue (e.g., α-synuclein fibrils, amyloid plaques, and / or tau tangles) for degradation; (ii) a ubiquitin ligase mobilizing ligand; and (iii) a proteolytically targeted chimera containing a linker between (i) and (ii). These proteolytically targeted chimeras are useful for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia.

The application provides a sleep quality improving relieving depression and tranquilizing composition and a preparation method and application thereof, and belongs to the technical field of health products.The relieving depression and tranquilizing composition comprises traditional Chinese medicine extracts, astaxanthin, theanine, probiotics and chitosan; the traditional Chinese medicine extracts are composed of polygala extract, jujube seed extract and albizia julibrissin extract. When prepared, the chitosan is mixed with an acetic acid solution to form a solution, the traditional Chinese medicine extracts, astaxanthin and theanine are added to prepare a suspension, and the suspension is mixed with the probiotics after vacuum freeze drying. Animal experiments show that the composition can shorten the sleep latency, prolong the total sleep time, and increase the contents of 5-hydroxytryptamine and gamma-aminobutyric acid in brain tissues, and can be used for preparing sleep improvement products, and has the effects of relieving depression and tranquilizing, soothing nerves, high safety and wide applicability.

The present application provides the use of aucubin or the combination of aucubin and ACA in the preparation of a medicament for treating ischemic brain injury, in particular acute cerebral ischemia-reperfusion injury. The present application first discovers that aucubin or the combination of aucubin and ACA can increase the blood flow of the ischemic side after ischemic brain injury in mice; significantly reduce the cerebral infarction volume; improve the cognitive and motor function of mice after ischemic brain injury; reduce the degree of injury caused by cerebral ischemia, significantly improve the degree of neuronal necrosis of brain tissue after ischemia; significantly increase the survival rate of HT22 cells after oxygen-glucose deprivation and reperfusion injury, reduce intracellular Ca 2+ fluorescence intensity, and inhibit cell apoptosis.

The application discloses a traditional Chinese medicine composition for senile dementia and stroke and a preparation method thereof, which is prepared from the following raw medicinal materials in parts by weight: 40 parts of Schinus molle, 10 parts of American ginseng, 8 parts of Panax notoginseng, 5 parts of hawthorn, 5 parts of Chinese yam, 5 parts of Herba Epimedii, 6 parts of Radix Curcumae, 5 parts of Poria cocos, 5 parts of Astragalus membranaceus, 5 parts of Codonopsis pilosula, 3 parts of Platycladus orientalis, 3 parts of Corydalis, and 5 parts of Cannabis sativa Linn. The application has the advantages that a nerve blood vessel unit system regulation mechanism is creatively proposed, the limitation of single target treatment is broken through, the Schinus molle, which is the monarch drug in the prescription, is rich in nervonic acid and neurotrophic factor-like substances, can directly act on neuron mitochondrial energy metabolism, improves brain tissue energy supply, and on the process level, the multi-stage dynamic extraction technology of the application innovates the traditional decocting mode.

This application relates to the field of pharmaceutical use technology, disclosing the application of a pharmaceutical composition in the preparation of drugs for the prevention or treatment of chronic alcoholic brain injury, developing a new use for Tongrentang Niuhuang Qingxin Pills, providing new therapeutic drugs and methods for the intervention and treatment of chronic alcoholic brain injury, thereby providing technical support for the rational use of drugs. This application demonstrates the therapeutic effect of Tongrentang Niuhuang Qingxin Pills on alcoholic brain injury through experiments on model rats, including the detection of learning and memory abilities, balance ability indicators, pathological changes in brain tissue, and S100-β in cerebrospinal fluid.